rs121912849
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM5PP2PP3_ModeratePP5_Very_Strong
The NM_000094.4(COL7A1):c.6187C>T(p.Arg2063Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000806 in 1,613,812 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2063G) has been classified as Pathogenic.
Frequency
Consequence
NM_000094.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL7A1 | NM_000094.4 | c.6187C>T | p.Arg2063Trp | missense_variant | 75/119 | ENST00000681320.1 | NP_000085.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL7A1 | ENST00000681320.1 | c.6187C>T | p.Arg2063Trp | missense_variant | 75/119 | NM_000094.4 | ENSP00000506558 | P1 | ||
COL7A1 | ENST00000328333.12 | c.6187C>T | p.Arg2063Trp | missense_variant | 74/118 | 1 | ENSP00000332371 | P1 | ||
COL7A1 | ENST00000487017.5 | n.2104C>T | non_coding_transcript_exon_variant | 40/83 | 5 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152116Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251234Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135868
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461696Hom.: 0 Cov.: 35 AF XY: 0.0000110 AC XY: 8AN XY: 727128
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152116Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74308
ClinVar
Submissions by phenotype
Recessive dystrophic epidermolysis bullosa Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2008 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant p.R2063W in COL7A1 (NM_000094.3) has been previously reported in affected patients (Ben Brick et al., 2014).Functional studies have demonstrated a damaging effect. The variant has been submitted to ClinVar as Pathogenic. The p.R2063W variant is observed in 2/1,13,580 (0.0018%) alleles from individuals of European (Non-Finnish) background in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 03, 2024 | Variant summary: COL7A1 c.6187C>T (p.Arg2063Trp) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251234 control chromosomes. c.6187C>T has been reported in the literature in the presumed compound heterozygous, compound heterozygous, or homozygous state in multiple individuals affected with autosomal recessive Dystrophic Epidermolysis Bullosa (example, Ben Brick_2014, Chen_2023, Hovanian_1997, Jerabkova_2010), including in at least 1 individual who carried a pathogenic variant in trans. Additionally, this variant was found in the heterozygous state in several individuals affected with dystrophic epidermolysis bullosa (example, Ben Brick_2014, Cuadro-Corrales_2010, Danescu_2015, Escamez_2010, Posteraro_2005), however parental genotype/phenotype correlations were not available. These data indicate that the variant is very likely to be associated with disease. In homozygous patient samples, this variant was associated with normal transcription and protein expression levels in at least 1 study (example, Hovanian_1997), however follow up studies in patient samples heterozygous for this variant found that collagen VII protein levels were reduced and altered (data not quantified) (example, Escamez_2010, Posteraro_2005). In vitro, this variant resulted in reduced fibroblast adhesion and keratinocyte migration, as well as increased susceptibility to protease digestion (example, Woodley_2008, Woodley_2021). The following publications have been ascertained in the context of this evaluation (PMID: 24170138, 36287101, 20920254, 25201089, 20184583, 9326325, 20598510, 16271705, 27899325, 18450758, 34674926). ClinVar contains an entry for this variant (Variation ID: 17456). Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 02, 2022 | Reported previously in the homozygous state or with a second COL7A1 variant in patients with autosomal recessive DEB (Hovnanian et al., 1997; Hashimoto et al., 1999; Gardella et al., 2002; Kern et al., 2009; Ben Brick et al., 2014; Kopeckova et al., 2016; Chen et al., 2020); Identified in unrelated patients with generalized DEB as a single heterozygous variant with no second COL7A1 variant identified (Posteraro et al., 2005; Escamez et al., 2010; Ben Brick et al., 2014; Danescu et al., 2015); Published functional studies demonstrate that this variant is located next to the helical interruption hinge region and results in local triple helix destabilization, and fibroblasts with this variant exhibit decreased motility and adhesion in vitro (Woodley et al., 2006); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20184583, 33969388, 21448560, 12207583, 19681861, 10232406, 18558993, 16271705, 12880418, 25201089, 15115517, 18030675, 26707537, 28830826, 34426522, 24170138, 35314946, 32484238, 9326325, 18450758) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2023 | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL7A1 protein function. ClinVar contains an entry for this variant (Variation ID: 17456). This missense change has been observed in individual(s) with autosomal recessive dystrophic epidermolysis bullosa (PMID: 9326325, 12207583, 28830826). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs121912849, gnomAD 0.002%). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 2063 of the COL7A1 protein (p.Arg2063Trp). Experimental studies have shown that this missense change affects COL7A1 function (PMID: 18450758). For these reasons, this variant has been classified as Pathogenic. - |
Epidermolysis bullosa dystrophica Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Biomedical Innovation Departament, CIEMAT | Oct 31, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at